Showing 2201-2210 of 5771 results for "".
- Staar Surgical Announces FDA IDE Clinical Study Approvalhttps://modernod.com/news/staar-surgical-announces-fda-ide-clinical-study-approval-2/2477164/Staar Surgical announced that the FDA, in a letter dated December 6, 2019, stated that it has determined that Staar has provided sufficient data to support initiation of a human clinical study in the United States of the EVO/EVO+ VISIAN Implantable Collamer Lens for Myopia, and EVO/EVO+ VISIAN To
- ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosahttps://modernod.com/news/proqr-announces-first-patient-dosed-in-phase-1-2-aurora-trial-of-qr-1123-for-autosomal-dominant-retinitis-pigmentosa/2477159/ProQR Therapeutics announced the first patient dosed in the phase 1/2 Aurora clinical trial of QR-1123 in patients with autosomal dominant retinitis pigmentosa (adRP). Initial data from the study are expected in 2021. “From previous clinical trials we have seen that RNA therapies can be a
- AI Diagnostics Company IDx Announces New Appointments to its Executive Leadership Teamhttps://modernod.com/news/ai-diagnostics-company-idx-announces-new-appointments-to-its-executive-leadership-team/2477153/IDx Technologies announced several new appointments to its executive leadership team to accelerate product development and scale operations to accommodate increased market adoption of IDx-DR, according to a company news release. IDx-DR is an FDA-authorized autonomous AI system that detects diabet
- Aldeyra Therapeutics Announces Topline Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Diseasehttps://modernod.com/news/aldeyra-therapeutics-announces-positive-topline-results-from-part-1-of-adaptive-phase-3-renew-trial-in-dry-eye-disease/2477138/Aldeyra Therapeutics announced positive topline results from Part 1 of the adaptive phase 3 RENEW trial of topical ocular reproxalap in patients with dry eye disease, according to a company news release. “To our knowledge, reproxalap is the first topical dry eye disease drug to demonstrate
- Acuity Eyecare Group Announces Rebranding and New Corporate Namehttps://modernod.com/news/acuity-eyecare-group-announces-rebranding-and-new-corporate-name/2477131/Acuity Eyecare Group, which operates leading eyecare groups across the U.S. and has backing by private equity group Riata Capital, is announcing a new name, AEG Vision, along with other corporate updates, according to a
- Alcon to Hold Second Annual Alcon Retina Fellows Institutehttps://modernod.com/news/alcon-to-hold-second-annual-alcon-retina-fellows-institute/2477120/Alcon announced it will host future ophthalmology leaders for the second annual Alcon Retina Fellows Institute, an educational experience where first year retina fellows gain hands-on surgical training and mentorship from some of the leading ophthalmologists in the field, according to a company n
- Clearwave Announces Interface with Modernizing Medicinehttps://modernod.com/news/clearwave-announces-interface-with-modernizing-medicine/2477113/Clearwave, a provider of patient check-in solutions via mobile, kiosk and desktop, announced a new interface with award-winning health IT company, Modernizing Medicine. This announcement comes as Modernizing Medicine’s 2019 user conference, MOMENTUM, kicks off in Orlando, Florida. The Clea
- Tarsius Pharma Announces Granting of Orphan Drug Designation for TRS by the European Medicines Agencyhttps://modernod.com/news/tarsius-pharma-announces-granting-of-orphan-drug-designation-for-trs-by-the-european-medicines-agency/2477104/Tarsius Pharma announced that the European Medicines Agency (EMA) approved the designation of orphan drug for its TRS for treatment of noninfectious uveitis and has acknowledged the clinically relevant advantage for TRS in noninfectious uveitis patients with glaucoma not eligible for corticostero
- Johnson & Johnson Vision Announces Availability of Acuvue Oasys with Transitions Light Intelligent Technology in the UKhttps://modernod.com/news/johnson-johnson-vision-announces-availability-of-acuvue-oasys-with-transitions-light-intelligent-technology-in-the-uk/2477102/Johnson & Johnson Vision announced the national availability of Acuvue Oasys with Transitions Light Intelligent Technology in the UK. The first-of-its-kind photochromic contact lens offers superior visual performance indoor and outdoor, day and night, according to a company news release.
- Aerie Pharmaceuticals Announces Agreement to Acquire Avizorex Pharma to Advance Its Dry Eye Programhttps://modernod.com/news/aerie-pharmaceuticals-announces-agreement-to-acquire-avizorex-pharma-to-advance-its-dry-eye-program/2477097/Aerie Pharmaceuticals announced it is acquiring Avizorex Pharma, a Spanish ophthalmic pharmaceutical company developing therapeutics for the treatment of dry eye disease. AVX completed a phase 2a study in dry eye subjects earlier this year with its lead product candidate, AVX-012. The acti